Ascletis Pharma Inc. has moved its oral obesity candidate ASC30 into global Phase 3 testing, dosing the first participant in a program expected to enroll approximately 4,600 adults with obesity or overweight across the United States, Europe and Canada. The program consists of the AURORA-1 and AURORA-2 pivotal trials, which will evaluate once-daily 20 mg, 40 mg and 60 mg maintenance doses over 72 weeks in people without and with type 2 diabetes, respectively. Ascletis expects topline Phase 3 results in the third quarter of 2028, followed by a potential U.S. Food and Drug Administration filing by the end of 2028 and a European submission in early 2029.
The timing puts ASC30 into one of pharmaceutical development’s most competitive races: finding an oral obesity medicine that can combine meaningful weight loss with the convenience of a tablet. Novo Nordisk already markets oral semaglutide as the Wegovy pill in the United States, while Eli Lilly and Company secured FDA approval in April 2026 for Foundayo, or orforglipron, a non-peptide small-molecule GLP-1 medicine that can be taken without food or water restrictions. Ascletis argues that ASC30 could become the second oral small-molecule GLP-1 receptor agonist available in the United States and Europe if development and regulatory review are successful.
Why could another oral GLP-1 pill attract attention when weight-loss drugs are already crowded?
Obesity treatment has rapidly moved beyond the original question of whether incretin medicines work. The next competitive phase is increasingly about how medicines are taken, how easily they can be manufactured, whether patients tolerate them sufficiently to stay on therapy and how widely healthcare systems can afford to provide them. Oral small molecules potentially avoid some manufacturing complexity associated with peptide injections and may appeal to patients who dislike needles, although commercial success will ultimately depend on efficacy, safety, price and convenience rather than tablet form alone.
The field is already becoming crowded enough that ASC30 cannot succeed merely by being oral. Eli Lilly’s Foundayo has an enormous head start and established Phase 3 evidence, while Novo Nordisk’s oral semaglutide has produced mean weight loss around 16.6% in the OASIS 4 development program. Other developers including Structure Therapeutics, Viking Therapeutics, Roche-linked programs and additional biotechnology companies are also pursuing oral or next-generation metabolic medicines, meaning an entrant expected to reach regulatory filing around the end of 2028 will need to demonstrate a clear clinical or commercial reason for physicians to switch.
How much weight loss has ASC30 produced so far?
The most important human efficacy evidence comes from a 13-week U.S. Phase 2 trial involving 125 participants with obesity. Patients receiving once-daily ASC30 achieved placebo-adjusted mean weight reductions of 5.4% at 20 mg, 7.0% at 40 mg and 7.7% at 60 mg, with the company reporting that weight loss had not reached a clear plateau by week 13. Mean baseline body weight was 107.3 kilograms and average body mass index was 38.6 kg/m², placing participants firmly within the population for whom substantial long-term weight reduction can have meaningful metabolic consequences.
Those figures are encouraging for an early-duration study, but they should not be directly compared with 68-, 72- or 80-week results from mature Phase 3 obesity programs. Weight loss with incretin therapy often continues over many months, so a 13-week result can establish dose response and biological activity without telling physicians what the eventual maintenance outcome will be. The AURORA studies are designed to provide that longer-duration answer across a much larger and more geographically diverse population.
Could gastrointestinal tolerability become ASC30’s biggest selling point?
Ascletis has consistently emphasized tolerability in its development narrative. In the Phase 2 obesity study, gastrointestinal adverse events were reported as grade 1 or grade 2 and occurred mainly during dose escalation, while no grade 3 or higher drug-related adverse events or serious adverse events were reported. The company also reported that weekly-titrated ASC30 produced approximately half the vomiting rate observed in a cross-study comparison with weekly-titrated orforglipron, although cross-trial comparisons are inherently less reliable than direct randomized head-to-head trials.
That qualification matters because gastrointestinal tolerability is one of the most commercially important issues across GLP-1 therapy. Nausea, vomiting, diarrhea and constipation can lead patients to delay escalation or discontinue treatment, and a medicine that produces slightly less weight loss but meaningfully better persistence could still become commercially competitive. AURORA will therefore need to establish not only how much weight patients lose at 72 weeks but how many remain on treatment long enough to achieve that benefit.
How will AURORA-1 and AURORA-2 test ASC30 differently?
AURORA-1 will study patients with obesity or overweight who do not have type 2 diabetes, while AURORA-2 will enroll participants whose obesity or overweight occurs alongside type 2 diabetes. Separating these populations is important because people with diabetes frequently lose less weight on incretin therapies than people without diabetes, meaning one aggregate study could obscure clinically meaningful differences. Both trials will investigate 20 mg, 40 mg and 60 mg maintenance doses over 72 weeks, giving Ascletis an opportunity to examine the relationship between efficacy and tolerability across three long-term exposure levels.
The company is also running a separate Phase 2 program examining ASC30 in type 2 diabetes, where endpoints include HbA1c, fasting glucose, body weight and safety. This broader metabolic-development strategy suggests Ascletis wants ASC30 to become more than an obesity-only medicine if the compound demonstrates competitive glucose-lowering performance. Success in both indications could increase commercial flexibility, although the regulatory timelines and evidence requirements will remain distinct.
Why are oral small-molecule GLP-1 drugs strategically different from oral semaglutide?
Oral semaglutide remains a peptide and therefore requires specialized formulation to survive gastrointestinal degradation and reach systemic circulation. Small-molecule GLP-1 receptor agonists such as orforglipron and ASC30 are chemically different and can potentially be manufactured through conventional small-molecule processes while avoiding some of the absorption restrictions historically associated with oral peptide therapy. Eli Lilly specifically markets Foundayo around the ability to take it at any time of day without food or water restrictions, making dosing simplicity a major competitive feature.
Ascletis will need to demonstrate whether ASC30 can deliver similarly straightforward everyday use while producing enough weight loss to justify entering a market where strong oral competitors already exist. The company’s Phase 3 decision suggests management believes the Phase 2 efficacy and tolerability package is sufficient to justify that investment, but the pivotal program will be much more demanding than the relatively small 125-patient Phase 2 study. Clinical execution across 4,600 participants will now determine whether ASC30 remains an interesting obesity candidate or becomes a credible global competitor.
What should the obesity-drug industry watch next?
The immediate milestone is enrollment progress, followed by whether the three maintenance doses can preserve the apparently favorable gastrointestinal profile observed earlier. Because Ascletis does not expect topline AURORA results until the third quarter of 2028, the competitive landscape will evolve substantially before ASC30 reaches a potential FDA filing. Eli Lilly, Novo Nordisk and several biotechnology challengers will have additional data and products by then, which raises the performance threshold ASC30 must clear.
That makes the 4,600-patient Phase 3 program a high-stakes bet rather than merely another obesity trial. The oral GLP-1 market is becoming large enough to support several products, but it is also becoming sophisticated enough that convenience alone will not guarantee adoption. ASC30’s opportunity depends on whether Ascletis can convert a 7.7% placebo-adjusted 13-week signal into durable, competitive 72-week weight loss without losing the tolerability profile that currently forms one of the strongest parts of its development story.
